Amryt Pharma Holdings logo

AMYT - Amryt Pharma Holdings Share Price

113.15p -3.3  -2.9%

Last Trade - 1:26pm

Sector
Healthcare
Size
Small Cap
Market Cap £183.7m
Enterprise Value £189.6m
Revenue £12.4m
Position in Universe 810th / 1816
Bullish
Bearish
Unlock AMYT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AMYT Revenue Unlock AMYT Revenue

Net Income

AMYT Net Income Unlock AMYT Revenue

Normalised EPS

AMYT Normalised EPS Unlock AMYT Revenue

PE Ratio Range

AMYT PE Ratio Range Unlock AMYT Revenue

Dividend Yield Range

AMYT Dividend Yield Range Unlock AMYT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMYT EPS Forecasts Unlock AMYT Revenue
Profile Summary

Amryt Pharma Holdings Limited, formerly Amryt Pharma plc, is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. Its products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. It holds a license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.

Directors
Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated December 20, 2004
Public Since April 27, 2007
No. of Shareholders: n/a
No. of Employees: 61
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share ,
Exchange London Stock Exchange (Full)
Shares in Issue 200,889,572
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AMYT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AMYT
Upcoming Events for AMYT
Wednesday 23rd October, 2019
Amryt Pharma Holdings Ltd Shares Magazine Investor Evening
Thursday 24th October, 2019
Amryt Pharma Holdings Ltd at Proactive Investors One2One Investor Forum
Tuesday 19th November, 2019
Amryt Pharma Holdings Ltd at Stifel Healthcare Conference
Wednesday 20th November, 2019
Amryt Pharma Holdings Ltd at Jefferies London Healthcare Conference
Thursday 21st November, 2019
Amryt Pharma Holdings Ltd at Proactive Investors One2One Investor Forum
Wednesday 27th November, 2019
Amryt Pharma Holdings Ltd Shares Magazine Investor Evening
Wednesday 15th April, 2020 Estimate
Full Year 2019 Amryt Pharma Holdings Ltd Earnings Release
Similar to AMYT
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.